AURA BIOSCIENCES INC
AURA · NASDAQ
Updated at 2026-10-13 14:43:15
- Today's High
- $6.56
- Today’s Low
- $6.38
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $6.55
- Previous Close
- $6.54
- Volume
- 613.13K
- Market Cap
- $678.22M
- P/E Ratio
- --
- EPS
- $-1.75
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 80 GUEST STREET, BOSTON, MA, UNITED STATES, 02135
- Country
- US
- Listing Date
- 2021-10-29
- Fiscal Year End
- December
- Shares Outstanding
- 103.44M
- CIK
- 0001501796
- Website
- aurabiosciences.com
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The company’s lead investigational therapy, AU-011, specifically targets ocular cancer cells, striving to eliminate tumors while safeguarding surrounding healthy tissue—demonstrating a commitment to precision oncology. With a robust pipeline designed to address critical unmet needs in cancer care and a highly experienced management team, Aura is strategically positioned to make significant advancements in the oncology market. Furthermore, its collaborative approach enhances innovation potential and aligns with the sector's growing demand for targeted therapies.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$48.06M
2026-03-31
$34.86M
2025-12-31
$27.23M
2025-09-30
$27.9M
Net Income
2026-06-30
-$45.63M
2026-03-31
-$33.68M
2025-12-31
-$25.55M
2025-09-30
-$26.13M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.48
2026-03-31
$-0.50
2025-12-31
$-0.37
2025-09-30
$-0.40
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$47.8M
2026-03-31
-$33.4M
2025-12-31
-$25.27M
2025-09-30
-$25.82M
Effective Tax Rate
2026-06-30
-0.06%
2026-03-31
-0.03%
2025-12-31
-0.05%
2025-09-30
-0.09%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $48.06M | $34.86M | $27.23M | $27.9M |
| Net Income | -$45.63M | -$33.68M | -$25.55M | -$26.13M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.48 | $-0.50 | $-0.37 | $-0.40 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$47.8M | -$33.4M | -$25.27M | -$25.82M |
| Effective Tax Rate | -0.06% | -0.03% | -0.05% | -0.09% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.